Skip to main content
. 2022 Jan 25;11(2):162–173. doi: 10.1159/000521613

Table 4.

Multivariable Cox regression analysis of OS and DFS

DFS
CSS
OS
n (%)* relative risk (95% Cl) p value n (%)** relative risk (95% Cl) p value n (%)*** relative risk (95% Cl) p value
CXCR1 +860, n (%) 0.008 0.001 0.001
CC§ 84 (84) 1 84 (84) 1 77 (83.7) 1
 GC 16 (16) 3.679 (1.399–9.672) 16 (16) 4.957 (1.922–12.781) 15 (16.3) 3.761 (1.727–8.190)
Hb, n (%) 0.003 0.012
 ≤12 38 (38) 2.805 (1.407–5.592) 38 (38) 2.392 (1.216–4.705)
 >12 62 (62) 1 62 (62) 1
Adjuvant therapy, n (%) 0.015 0.032
 No 63 (63) 1 63 (63) 1
 Yes 37 (37) 2.359 (1.180–4.715) 37 (37) 2.072 (1.067–4.024)
L, n (%) 0.008
 L0 75 (81.5) 1
 L1 17 (18.5) 2.743 (1.301–5.783)
CCI, n (%) 0.017
 ≤40 47 (51.1) 1
 >40 45 2.311 (1.158–4.613)

Only significant variables and outcomes are shown. Significant parameters in univariate analysis were included in the respective multivariate analysis for DFS, CSS, and OS. For DFS, hemoglobin (≤12/>12 g/dL), intraoperative blood and FFP transfusions, tumor grading (G1-2/G3-4), UlCC (I-II/III-IV), N category (pN0/pN1), CCI (≤40/>40), adjuvant therapy, and the CXCR1 +860C>G SNP were included. For CSS, EBD, hemoglobin (≤12/>12 g/dL), intraoperative blood and FFP transfusions, tumor grading (G1-2/G3-4), UICC (I-II/III-IV), N category (pN0/pN1), ICU time (≤1/>1 day), CCI (≤40/>40), adjuvant therapy, and the CXCR1 +860C>G SNP were included. For OS, preoperative cholangitis, hemoglobin (≤12/>12 g/dL), intraoperative blood and FFP transfusions, lymphovascular invasion, tumor grading (G1-2/G3-4), UICC (I-II/III-IV), tumor stage (pT1-2/pT3-4), N category (pN0/pN1), ICU time (≤1/>1 day), CCI (≤40/>40), tumor recurrence, and the CXCR1 +860C>G SNP were included.

*

100 patients with complete data were included in the model.

**

100 patients with complete data were included in the model.

***

92 patients with complete data were included in the model.

§

Determined as the favorable allele.